Although HLA-DRA gene expression was recognized as an independent adverse prognosis factor for RFS in DLBCL 57, we did not find any association with patient outcome in PCNSL, a result that may be linked to the poorer overall outcome of patients with PCNSL compared to DLBCL 58. The gene discussed is HLA-DRA; the disease is primary central nervous system lymphoma.